Meng‐Ru Shen

National Cheng Kung University

Papers

1

Total Citations

10

H-Index

1

About

Dr. Meng‐Ru Shen is a leading oncologist and researcher whose work centers on improving outcomes for women with gynecologic malignancies, particularly ovarian, tubal, and peritoneal cancers. Her major contributions lie in bridging the gap between clinical trial efficacy and real-world effectiveness, with a strong focus on targeted therapies. Her landmark study, the "ROBOT" trial, is a seminal piece of work that provides critical, long-term data on the use of bevacizumab in Asian patients. This eight-year retrospective analysis, cited 10 times, offers invaluable insights into the drug's prognostic impact and adverse effects in both front-line and relapse settings, addressing a significant gap in the literature for this population. By meticulously documenting the real-world experience of a large patient cohort, Dr. Shen has provided clinicians with essential evidence to guide treatment decisions. Her work is a testament to the importance of pragmatic clinical research, ensuring that the benefits of advanced therapies are understood and accessible in diverse patient populations, directly influencing practice patterns and improving the standard of care for women battling these challenging cancers.

Research Focus

Key Achievements

1
H-Index
1
Papers
10
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
10 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: National Cheng Kung University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago